Compare Agilent Technologies Inc (A) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilent Technologies Inc vs Raymond James Financial, Inc. — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.00B), while Raymond James Financial, Inc. trades at $179.97 (market cap $33.96B). The key difference: Agilent Technologies Inc is the larger of the two by market cap, and Raymond James Financial, Inc. pays the higher dividend (1.22%). Which is the better fit depends on your goals.
| A | RJF | |
|---|---|---|
Market Cap | $42.00B | $33.96B |
Sector | Health | Financials |
52-Week High | $157.20 | $180.55 |
52-Week Low | $110.24 | $140.89 |
Enterprise Value | $43.55B | — |
Dividend Yield | 0.69% | 1.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
Raymond James Financial (RJF) trades at $176.56, down 1.54% on the day, with a bullish technical signal supported by moving averages and strong quarterly earnings beats. Revenue and net income have grown steadily, with Q3 2026 reaching record revenues of $3.93 billion, up 16% year-over-year. The stock is supported by positive analyst sentiment and a consensus price target of $183.75.
The outlook for RJF is positive, driven by earnings growth and strategic acquisitions, though risks include market volatility and competitive pressures. With no sell ratings and a dividend payout, the stock presents a stable opportunity for investors seeking exposure to financial services, balanced by the need to monitor expense management and economic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
